In February of 2008, Amira signed a global agreement with GlaxoSmithKline to develop, manufacture and commercialize FLAP inhibitors.

Commenting on the agreement, Dave Allen, SVP Respiratory Centre of Excellence in Drug Discovery, GlaxoSmithKline said: “The role of anti-leukotriene agents has been well validated in the treatment of respiratory diseases. We are very excited at entering into this global agreement with Amira to deliver novel therapies to patients based on this mechanism”.

Feb. 4, 2008 Amira Pharmaceuticals and GlaxoSmithKline enter global agreement for FLAP inhibitor program.
<more>

Business Development inquiries
Hari Kumar, Chief Business Officer
Tel: +1 858 228 4683
Email: hari.kumar@amirapharm.com